Prolonged response to osimertinib in EGFR exon 20 insertion and SETD2 loss-of-function mutation in advanced NSCLC: a molecular paradox
Content available only in Spanish.
Tako-Tsubo syndrome after alectinib initiation
Introduction Anaplastic lymphoma kinase (ALK) inhibitors have revolutionized the treatment of ALK-positive non-small cell lung cancer (NSCLC), significantly improving survival and quality of life. Among second-generation ALK inhibitors, alectinib has been widely used due to its superior efficacy and safety profile compared to first-generation agents like crizotinib, as demonstrated in the phase III ALEX trial1 […]
Long-term survivor with advanced small-cell lung carcinoma: the role of maintenance immunotherapy and local treatment of oligoprogression
Content available only in Spanish.
Clinical-radiological discordance after neoadjuvant chemoimmunotherapy in resectable lung squamous cell carcinoma
Content available only in Spanish.
Cardiac tamponade as the initial presentation of metastatic lung adenocarcinoma with high PD-L1 expression
Content available only in Spanish.
EGFR appears to be, and BRAF may be too
Content available only in Spanish.
Beyond 0%: durable response to chemoimmunotherapy in PD-L1-negative non-small cell lung cancer
Content available only in Spanish.
PD-L1 after neoadjuvant therapy: an adjuvant treatment dilemma
Content available only in Spanish.
Clinical challenges in the management of stage III EGFRmutated non-small cell lung cancer: integrating surgery and adjuvant therapy in the post-ADAURA era
Content available only in Spanish.
ALK metamorphosis: a diagnostic and therapeutic challenge
Content available only in Spanish.